No results found.
April 5-6, 2012: Connecting patient care, research, and scientific advancement
This on-campus research symposium aims to bring together members of campus and the surrounding community to foster interdisciplinary discussions on cancer research and its affects on patient care. In order to increase understanding and awareness, we will discuss in an open forum with research talks, poster presentations, and panel discussions. We invite community members, clinicians, and researchers from UIUC and other Midwest regional institutions from departments ranging from the social sciences to basic sciences to engineering and medicine.
The symposium features invited talks from nationally-recognized cancer researchers, oral presentations from UIUC faculty and students, and poster sessions. We encourage student researchers from UIUC and from other regional schools to apply (travel awards are available).
About CC@I Symposium
The Cancer Community at Illinois (CC@I) Symposium is organized by a group of students on the University of Illinois campus to bridge the areas of social science, basic sciences to engineering and medicine as they relate to cancer. The symposium mission is to: 1) Facilitate interdisciplinary collaboration and understanding that transcends established departmental affiliation; 2) Foster an increased understanding of the social and environmental factors affecting patients; and 3) Develop unique vantage points afforded by interactive dialogue between and among the various cancer research disciplines. In order to accomplish this, the symposium will engage the local patient community through use of the nascent social and support efforts of the Mills Breast Cancer Institute, Carle Hospital, and regional clinical collaborators.
If you are interested in other CC@I events or the program in general, please contact email@example.com
The goals of the present work are to engineer a high affinity TCR specific for the clinically relevant tumor antigen WT-1 bound to the class I MHC product HLA.A2 using yeast display, and to express a soluble form of this high affinity TCR in E. coli. Subsequent experiments will explore the activity of single-chain TCRs (scTCRs) as fusions to cytokines for enhanced immune responses.
The prevalence of WT-1 in many human tumors makes it a suitable candidate for the development of a high affinity TCR. Given the undesirable side effects of current cancer therapies, an adoptive immunotherapy utilizing high affinity TCRs provides an attractive alternative to current treatments. High affinity TCRs could provide a tumor specific method to enhance the immune response and eliminate tumors effectively with minimal side effects.
-From David Aggen's Research Synopsis
The Focal Point Project by the Graduate College
Researchers should cite this work as follows:
David H. Aggen (2012), "[Illinois] Cancer Community Symposium 2012: T Cell Receptors For Potential Cancer Immunotherapy Applications: Single Chain T Cell Receptors Circumvent Mispairing with Endogenous TCR and Mediate T Cell Activity," https://nanohub.org/resources/13951.
Beckman Institute, University of Illinois at Urbana-Champaign, Urbana, IL